BC060267 Activators
Efcab12, characterized by its EF-hand calcium binding domain, exhibits expression in various neuroanatomical structures, including the 4th ventricle lateral recess, choroid plexus, lateral ventricle choroid plexus, and olfactory epithelium. As an ortholog to human EFCAB12, its precise function in calcium signaling pathways is vital for cellular processes within these tissues. Activation of Efcab12 involves a sophisticated interplay with multiple chemicals. Ryanodine, a receptor agonist, activates Efcab12 through increased intracellular calcium levels, impacting its EF-hand calcium binding domain. Thapsigargin, a SERCA inhibitor, indirectly activates Efcab12 by depleting ER calcium stores. Bay K8644, a calcium channel activator, influences Efcab12 through increased calcium entry. A23187, a calcium ionophore, activates Efcab12 by inducing calcium influx. Nimodipine, a calcium channel blocker, indirectly activates Efcab12 by preventing calcium entry.
Dantrolene, a receptor antagonist, inhibits Efcab12 activation by reducing intracellular calcium levels. Ionomycin, another calcium ionophore, activates Efcab12 through elevated intracellular calcium levels. Nifedipine, a calcium channel blocker, indirectly activates Efcab12 by preventing calcium entry. U73122, a PLC inhibitor, disrupts Efcab12 activation by altering intracellular calcium release. N-Phenylthiourea, a TRPA1 antagonist, blocks Efcab12 activation by reducing calcium entry. SKF 96365, a non-specific calcium channel blocker, indirectly activates Efcab12. Ruthenium Red, a calcium channel blocker, inhibits Efcab12 activation by reducing calcium entry. This intricate web of chemical regulators highlights the importance of calcium signaling pathways in modulating Efcab12. The targeted activation of Efcab12 through these chemicals offers a nuanced perspective on the intricate cellular processes and signaling cascades influenced by its EF-hand calcium binding domain.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Ryanodine receptor agonist impacting calcium release from the endoplasmic reticulum. Activates Efcab12 through increased intracellular calcium levels, influencing its EF-hand calcium binding domain and potentially regulating downstream processes in calcium signaling pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA inhibitor disrupting calcium homeostasis. Indirectly activates Efcab12 by depleting ER calcium stores, triggering a compensatory response and potentially influencing its EF-hand calcium binding domain, modulating downstream signaling cascades in response to changes in calcium signaling. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
L-type calcium channel activator affecting calcium influx. Activates Efcab12 through increased calcium entry, potentially influencing its EF-hand calcium binding domain and regulating downstream processes in calcium signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Calcium ionophore inducing calcium influx. Activates Efcab12 by elevating intracellular calcium levels, potentially influencing its EF-hand calcium binding domain and modulating downstream signaling cascades in response to changes in calcium signaling. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
L-type calcium channel blocker impacting calcium influx. Indirectly activates Efcab12 by preventing calcium entry, triggering a compensatory response and potentially influencing its EF-hand calcium binding domain, modulating downstream signaling cascades in response to changes in calcium signaling. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Ryanodine receptor antagonist affecting calcium release from the endoplasmic reticulum. Inhibits Efcab12 activation by reducing intracellular calcium levels, potentially impacting its EF-hand calcium binding domain and downstream signaling cascades in response to changes in calcium signaling pathways. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Calcium ionophore inducing calcium influx. Activates Efcab12 by elevating intracellular calcium levels, potentially influencing its EF-hand calcium binding domain and modulating downstream signaling cascades in response to changes in calcium signaling. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
L-type calcium channel blocker impacting calcium influx. Indirectly activates Efcab12 by preventing calcium entry, triggering a compensatory response and potentially influencing its EF-hand calcium binding domain, modulating downstream signaling cascades in response to changes in calcium signaling. | ||||||
N-Phenylthiourea | 103-85-5 | sc-236086 | 100 g | $319.00 | ||
TRPA1 antagonist inhibiting calcium influx. Blocks Efcab12 activation by reducing calcium entry, potentially influencing its EF-hand calcium binding domain and modulating downstream signaling cascades in response to changes in TRPA1-mediated calcium signaling pathways. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
Non-specific calcium channel blocker impacting calcium influx. Indirectly activates Efcab12 by preventing calcium entry, potentially influencing its EF-hand calcium binding domain, modulating downstream signaling cascades in response to changes in calcium signaling. | ||||||